Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13434315 | 0.88 | PDE4B (0.44) | HSD11B1PDE4BPDE4DKMT2AMEN1 | |
| SCHEMBL3487423 | 0.84 | REN (0.53) | — | |
| SCHEMBL3488892 | 0.84 | REN (0.53) | — | |
| SCHEMBL3488928 | 0.83 | NPC1 (0.50) | KMT2AMEN1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL3487167 | 0.82 | REN (0.43) | — | |
| SCHEMBL3488451 | 0.82 | POLB (0.38) | KMT2AMEN1POLBALDH1A1HPGD | |
| SCHEMBL3487502 | 0.81 | REN (0.43) | PDE4BPDE4DPOLBHPGDHSD17B10 | |
| SCHEMBL2243465 | 0.80 | HTT (0.41) | KMT2AMEN1L3MBTL1ALDH1A1HPGD | |
| SCHEMBL3487243 | 0.79 | REN (0.46) | L3MBTL1POLBHPGDHSD17B10 | |
| SCHEMBL3488571 | 0.79 | REN (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | HSD11B1 42/4885PDE4B 1175/4885PDE4D 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.